Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012
Cash flows from operating activities of continuing operations:
Net loss	$ (15,593)		$ (12,134)
Loss from discontinued operations	(1,358)		(2,193)
Net loss from continuing operations	(14,235)		(9,941)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities of continuing operations:
Deconsolidation of French Subsidiaries	(641)		0
Gain on contract settlement	(534)		0
Depreciation and amortization	57		510
Accretion of debt discount	192		0
Stock-based compensation expense	(1,622)		(1,722)
Changes in derivative liabilities	243		0
Accretion of interest on contingent consideration	242		0
Other	17		(2)
Changes in operating assets and liabilities of continuing operations, net of assets and liabilities acquired and divested in business acquisitions and divestitures:
Accounts receivable	276		(2,491)
Inventories	(338)		(109)
Prepaid expenses and other current assets	(63)		(926)
Deferred rental income and other assets	1		(436)
Accounts payable	(1,502)		279
Accrued expenses	(39)		562
Accrued compensation	(917)		0
Deferred revenue	(248)		225
Deferred compensation	(165)		68
Other liabilities	(21)		171
Net cash used in operating activities from continuing operations	(16,053)		(10,368)
Cash flows from investing activities of continuing operations:
Purchase of fixed assets	(119)		(23)
Proceeds from the sale of property and equipment	3,657		2
Investment in intangible assets	0		836
Cash acquired from Finesco	0		1,855
Elimination of bank deficit in deconsolidated French Subsidiaries	270		0
Deposit of restricted cash	(280)		0
Net cash provided by investing activities from continuing operations	3,528		2,670
Cash flows from financing activities of continuing operations:
Proceeds from exercise of warrants	46		40
Proceeds from the exercise of stock options	0		10
Repayment of capital lease obligations	0		(3)
Issuance of common stock, net of offering costs	16,612		19,489
Net cash provided by financing activities from continuing operations	16,658		19,536
Cash flows from discontinued operations:
Net cash used in operating activities of discontinued operations	(144)		(1,279)
Net cash provided by (used in) investing activities of discontinued operations	1,500		(1,260)
Net cash provided by (used in) discontinued operations	1,356		(2,539)
Effect of exchange rate changes on cash	0		127
Net increase in cash and cash equivalents	5,489		9,426
Cash and cash equivalents, beginning of period	15,130	[1]	7,435
Cash and cash equivalents, end of period	20,619		16,861
Supplemental disclosure of cash flow information:
Cash paid for interest	189		223
Non-cash investing and financing activities:
Issuance of 486,923 shares of common stock upon conversion of convertible note	1,737		0
Receivable from buyer upon sale of BQ Kits	51		0
TopoTarget
Non-cash investing and financing activities:
Issuance of common stock for acquisition	1,543		0
Finesco
Non-cash investing and financing activities:
Issuance of common stock for acquisition	0		8,556
PediatRx Inc.
Non-cash investing and financing activities:
Issuance of 373,134 shares of common stock to PediatRx Inc. for co-promote agreement	$ 0		$ 1,000

[1] The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.